GlassScriptPhysician profile
Alexander James Johnson
NPI 1275055956
$1,497.70
in general payments reported to CMS, 2019-2025
24 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $326 · 2023: $308 · 2024: $259 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.20 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $194.74 | 2021 | |
| Genzyme Corporation | $170.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $132.45 | 2024-2025 | |
| Blueprint Medicines Corporation | $127.57 | 2022 | |
| Pfizer INC. | $114.12 | 2023-2025 | |
| Eisai INC. | $102.82 | 2022 | |
| Adc Therapeutics America, INC. | $100.50 | 2023 | |
| Sanofi-Aventis U.S. LLC | $95.66 | 2022 | |
| Janssen Biotech, INC. | $69.08 | 2025 | Talvey, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $59.05 | 2023-2024 | Keytruda |
| Abbvie INC. | $50.44 | 2024-2025 | |
| Lilly USA, LLC | $46.92 | 2023-2024 | Jaypirca, Verzenio |
| Seagen INC. | $36.41 | 2023 | Padcev, Tukysa |
| Pharmaessentia USA Corporation | $22.19 | 2025 | Besremi |
| Celgene Corporation | $21.61 | 2024 | Reblozyl |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $20.81 | 2024 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $20.07 | 2024 | Qinlock |
| Taiho Oncology, INC. | $19.47 | 2025 | |
| Geron Corporation | $17.23 | 2025 | Rytelo |
| E.R. Squibb & Sons, L.L.C. | $16.03 | 2025 | Opdivo |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Rigel Pharmaceuticals, INC. | $15.39 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Ipsen Biopharmaceuticals, INC | $14.42 | 2024 | Onivyde, Somatuline Depot |
| Foundation Medicine, INC. | $14.01 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.